Nabsys Releases New Nanodetector Chips, Increasing Throughput of its HD-Mapping Platform


August 11, 2021 / Providence, RI: Nabsys, the pioneer in electronic whole-genome mapping, announces the release of its next-generation HDM-5 Chip™ for HD-Mapping™. This most recent development has contributed to a 10-fold increase in throughput over the last nine months. Customers are receiving shipments of these next-generation chips this month.

CEO and Founder, Barrett Bready said, “The release of our new higher-throughput HDM-5 Chip clearly demonstrates the scalability of HD-Mapping. We have addressed all technical challenges associated with electronic detector scaling, clearing the path to routine, accurate, cost-effective analysis of genomic structural variation, including next-generation cytogenomics.” John Oliver, Nabsys CTO, added, “This is really just the beginning for electronic whole-genome mapping. Nabsys is pushing the boundaries of DNA mapping by employing electronic detection to achieve higher resolution than is possible with other technologies. We are continually innovating with HD-Mapping to further increase throughput, explore new application areas, and advance data analysis tools while reducing per sample cost.”

About HD-Mapping
These characteristics make HDM an ideal first-line approach for a variety of applications for small and large genomes, including genome assembly, structural variant analysis, and strain identification. The HD-Mapping system is a total whole-genome mapping solution including the HD-Mapping instrument, electronic nanodetector chips, sample-preparation kits, run reagents, and advanced analytical software tools.

Brian Paras VP, Commercial Development

HD-Mapping Systems Shipping to Customers

Nabsys is now shipping HD-Mapping systems in fulfillment of customer orders.

HD-Mapping provides high-resolution, high-definition electronic detection that supports a variety of genomic mapping applications, across a wide range of organisms.

For product information, availability, and pricing please contact us at

Learn more about High-Definition whole-genome mapping at

3 HD-Mapping systems shipping to customer labs

Nabsys Raises $21 Million Equity Round Led by Hitachi High-Technologies

PROVIDENCE RI (October 2, 2019) Nabsys, the pioneer in high-definition genome mapping, announced today that it has closed on a $21 million equity round led by Hitachi High-Technologies Corporation.

Nabsys will use the funding to finalize product development and support global commercial launch of their HD-Mapping™ whole-genome electronic mapping platform.

HD-Mapping has applications in a wide variety of key research applications, including de novo assembly, structural variant analysis, metagenome characterization, and strain identification, as well as in next-generation cytogenetics. Nabsys electronic mapping enables routine, scalable analysis of genomic structural variation.

Mr. Tsuyoshi Ogino, General Manager, Innovation Division at Hitachi High-Technologies said, “There is a strong need for accurate, robust, and scalable genomic structural analysis for cytogenetic, cancer, and infectious disease research. Hitachi High-Technologies determined that the Nabsys HD-Mapping approach effectively supports this need. The company is also a strong fit with our strategy for continued advanced R&D with strategic investments in life sciences.”

“This investment round will help Nabsys fulfill its mission to make the analysis of large- and intermediate-scale genomic variation as routine, accurate, and cost-effective as the analysis of single-nucleotide variation,” said Barrett Bready, M.D., Founder and CEO at Nabsys.

About Hitachi High-Technologies Corporation:
Hitachi High-Technologies Corporation, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including Analytical & Medical Solutions (manufacture and sales of clinical analyzers, biotechnology products, and analytical instruments), Nano-Technology Solutions (manufacture and sales of semiconductor manufacturing equipment and analysis equipment), and Industrial Solutions (providing high value-added solutions in fields of social & industrial infrastructures and mobility, etc.). The company’s consolidated revenues for FY 2018 were approx. JPY 731.1 billion [USD 6.6 billion]. For further information, visit

About Nabsys:
Nabsys is the leader in high-definition electronic genome mapping. Nabsys uses proprietary electronic nanochannel detectors to analyze long DNA molecules at high velocity. Nabsys HD-Mapping™ whole genome maps with sub-diffraction-limit resolution, provide compelling advantages for the analysis of genomic structural variation, genome assembly, and high-specificity strain identification. For further information, visit


Brian Paras VP, Commercial Development